HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Denali Therapeutics (NASDAQ:DNLI) but lowers the price target from $95 to $90.
August 05, 2024 | 7:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Denali Therapeutics but lowers the price target from $95 to $90.
The Buy rating suggests continued confidence in Denali Therapeutics' prospects, but the lowered price target indicates a slightly more conservative outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100